Mayo Clinic (Mayo MN, Mayo FL, UMMC)
The Mayo Clinic MarkVCID program is located at three sites: Mayo Clinic Rochester (MCR) in Rochester, MN, Mayo Clinic Florida (MCF) in Jacksonville, FL, and the University of Mississippi Medical Center (UMMC) in Jackson, MS.
Ron Petersen MD, PhD (PI) is a behavioral neurologist at MCR, Director of the Mayo Clinic Alzheimer’s Disease Research Center and the Mayo Clinic Study of Aging, and Co-Director of the Clinical Core for the Alzheimer’s Disease Neuroimaging Initiative. Prashanthi Vemuri, PhD, (co-PI) is a neuroimaging scientist at MCR with expertise in imaging of neurodegenerative disorders and development and validation of imaging biomarkers for Alzheimer’s disease and cerebrovascular disease. Her background is in image acquisition and processing MRI and PET images and computational technologies.
Gregory Day, MD (PI) is an Assistant Professor of Neurology at MCF and a full-time clinician-researcher. His scientific efforts are devoted to improving early recognition and characterization of individuals with common and uncommon presentations of neurodegenerative dementing diseases, including determination of the contributors to cognitive decline.
Thomas Mosley, PhD (PI) is a clinical neuropsychologist and founding director of the Memory Impairment and Neurodegenerative Dementia (MIND) Center at the University of Mississippi Medical Center. He has an extensive background in neuropsychological assessment, behavioral neurology, and population-based studies in neuroepidemiology with a particular focus on race/ethnic disparities and vascular contribution to brain aging, cognitive decline, and dementia.
Study Recruitment
The Mayo Clinic MarkVCID program will focus on recruiting a diverse group of 200 participants. MCR plans to enroll 120 white participants while MCF will enroll 40 Hispanic participants, and UMMC will enroll 40 African American participants. All three sites will use the same clinical evaluation and imaging protocols.
MCR serves as the central IRB for the three sites, but each has developed its own recruitment strategy. The MCR clinical team plans to recruit MarkVCID participants from the registry of the Rochester Epidemiology Project (REP), which includes patients in the Mayo Clinic Health System in southeastern Minnesota, southwestern Wisconsin, and northeastern Iowa. This 27-county region has electronic health care records available to screen participants for hypertension (HTN), diabetes mellitus (DM) and cognitive impairment.
To enroll participants of Hispanic/Latin ethnicity, MCF has focused on expanding outreach, recruitment, and engagement within northeast Florida. In partnership with Mayo colleagues and local Hispanic community leaders, they have established connections with community government leaders, Hispanic churches, and local media, and participated in Spanish radio/TV interviews and public health fairs advocating for research participation.
The UMMC site is committed to enrolling African American participants in MarkVCID. Approximately 60% of UMMC Cardiometabolic Clinic participants scheduled in a month meet criteria for inclusion in the MarkVCID study.
Study Team
MCR
Ronald Petersen, MD, PhD, Principal InvestigatorPrashanthi Vemuri, PhD, Multiple Principal Investigator
Jonathan Graff-Radford, MD, Co-Investigator
Clifford Jack, Jr. MD, Co-Investigator
Walter Kremers, PhD, Co-Investigator
MCF
Gregory Day, MD, Site Principal InvestigatorNeill Graff-Radford, MD, Co-Investigator
Christian Lachner, MD, Co-Investigator
Richard White, MD, Co-Investigator
Floyd Willis, MD, Co-Investigator
UMMC
Thomas H. Mosley, Jr., PhD, Site Principal InvestigatorB. Gwen Windham, MD, MHS, Co-Investigator
Michael E. Griswold, PhD, Co-Investigator
